Heart surgery product developer Admedus (ASX: AHZ) has received approvals for its first in-human trial at Leuven University Hospital of the company’s proprietary ADAPT single-piece 3D aortic valve.
The Belgian surgeon Professor Bart Meuris will conduct the trial of 15 patients who will be followed up six month after receiving the ADAPT implant.
Results of the trial, which could open up the $3 billion aortic valve replacement (TAVR) market for the company, will be known early in 2021.
Meuris has previously implanted the ADAPT valve in six sheep, which are a recognised model for heart value implantation.
ADAPT consists of a bio-scaffold material which has proven durable and resistant to calcification over 10 years of trials.
In the sheep trials ADAPT functioned normally after implantation and was stable after six months.
Admedus CEO Wayne Paterson said the trial approval was an endorsement of the ADAPT valve technology and an important step in the product’s development.
Subscribe to our free @AuManufacturing newsletter here.